创模生物科技(北京)有限公司

CN / En

NEWS

Functionality of the 3D organoid platform of InnoModels Biotechnology

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-08-09 10:50
  • Views:

(Summary description)In the fast-changing world of biotechnology, InnoModels Biotechnology (Beijing) Co., Ltd. has brought breakthroughs in the fields of new drug discovery, disease modeling and personalized medicine with its innovative 3D organoid platform. Based on the clinical tumor biosample library, the platform realizes the seamless integration of the whole process from in vitro high-throughput screening to in vivo research through advanced technological means, providing strong support for researchers.

Functionality of the 3D organoid platform of InnoModels Biotechnology

(Summary description)In the fast-changing world of biotechnology, InnoModels Biotechnology (Beijing) Co., Ltd. has brought breakthroughs in the fields of new drug discovery, disease modeling and personalized medicine with its innovative 3D organoid platform. Based on the clinical tumor biosample library, the platform realizes the seamless integration of the whole process from in vitro high-throughput screening to in vivo research through advanced technological means, providing strong support for researchers.

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-08-09 10:50
  • Views:
Information

In the fast-changing world of biotechnology, InnoModels Biotechnology (Beijing) Co., Ltd. has brought breakthroughs in the fields of new drug discovery, disease modeling and personalized medicine with its innovative 3D organoid platform. Based on the clinical tumor biosample library, the platform realizes the seamless integration of the whole process from in vitro high-throughput screening to in vivo research through advanced technological means, providing strong support for researchers.
Rapid Prediction and Drug Screening
A core function of the 3D organoid platform of InnoModels Biotechnology is the rapid prediction of drug efficacy in the clinic. This feature enables researchers to obtain critical feedback in the early stages of drug development so that they can make timely adjustments to their R&D strategies. In addition, the platform is able to screen compounds with higher development potential from a wide range of alternatives, greatly optimizing resource allocation and accelerating the process of new drug development.
Model Screening and Efficacy Comparison
On the basis of drug screening, the platform can also select the most suitable model for subsequent in vivo experiments based on the response of the drug to the model. This feature ensures the consistency and reliability of experimental data, providing researchers with more accurate experimental results. At the same time, by comparing with counterpart drugs or clinical therapeutic drugs, the platform can intuitively demonstrate the differences in efficacy and effective models, providing a strong basis for further optimization of drugs.
Disease specificity analysis and drug resistance analysis
For different types of cancers, the 3D organoid platform from InnoModels Biotechnology is able to compare the efficacy differences between different cancer model cohorts to determine the best indication for a drug. This feature is important for improving drug targeting and effectiveness. In addition, the platform is able to differentiate models into effective and resistant models based on efficacy data, and based on the differences in genetic features between models and before and after treatment, it can deeply explore the mechanism of action and resistance of drugs to provide more scientific guidance for clinical drug use.

 


Biomarker Discovery
The 3D organoid platform of InnoModels also has the function of biomarker discovery. By categorizing models according to their efficacy and analyzing the differences in genetic characteristics of different groups based on histology, researchers can find biomarkers that can predict drug efficacy. These biomarkers not only help in the precise treatment of drugs, but also provide an important reference for the early diagnosis and prognosis assessment of diseases.
Advantages of 3D organoid technology
The 3D organoid platform of InnoModels Biotechnology has such powerful functions thanks to its 3D organoid technology. Compared with traditional 2D cell culture and animal experiments, 3D organoids can better simulate the natural physiological processes of cells, providing more accurate models of human disease development and more clinically valuable research results. In addition, 3D organoids have realistic microanatomical structures and organ-specific cell types, and can even mimic part of an organ's function, making the research results closer to the real situation.
Summarization
In summary, the 3D organoid platform of InnoModels Biotechnology has shown great potential and value in the field of biotechnology by virtue of its powerful functions such as rapid prediction, drug screening, model screening, efficacy comparison, disease specificity analysis, drug resistance analysis, and biomarker discovery. The platform not only accelerates the process of new drug development and improves the targeting and effectiveness of drugs, but also provides powerful support for early diagnosis, prognosis assessment and personalized treatment of diseases. In the future, with the continuous progress and improvement of the technology, the 3D organoid platform will certainly play an even more important role in the field of biotechnology.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司